Pharma News

Lincoln Pharma tanks 20% after product ban in Tanzania Lincoln Pharmaceuticals was locked in lower circuit of 20% at Rs 179 on the BSE after the company said thatTanzania drug authority (TFDA) has announced to stop and banned importing of Chloramphenicol Sodium Succinate Injection and also cancelled the company’s registration. “In this circumstance a huge quantity dispatched by the company ... Read More »

UniQure’s gene therapy increases clotting in some hemophilia B patients UniQure said preliminary results from the low-dose cohort in a phase I/II clinical trial assessing its AAV5/FIX gene therapy, AMT-060, in patients with moderately severe to severe hemophilia B demonstrated a significant clinical benefit in two participants. The company said all five patients in the low-dose cohort had Factor IX ... Read More »

Glenmark receives tentative US FDA approval for generic Multaq tablets Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (US FDA) for its dronedarone tablets, 400 mg, the generic version of Multaq tablets, 400 mg of Sanofi-Aventis US, LLC. ‘Tentative approval’ means that FDA has concluded that a drug product has ... Read More »

SMS Pharma rises 12% on USFDA nod for Andhra Pradesh plant Shares of SMS Pharmaceuticals  climbed 11.8 percent in early trade Monday on getting approval from the US health regulator for one of its unit in Andhra Pradesh. “SMS has received approval from the US Food and Drug Administration (USFDA) for manufacturing facility (unit 7) located at Kandivalasa village, Pusapatirega ... Read More »

Indian pharma market crosses Rs 1,00,000 crore mark: IMS Health  MUMBAI: The Indian pharmaceutical market has for the first time crossed the Rs 100000 crore mark in November when calculated on the basis of Moving Annual Total (MAT), said IMS Health, a global pharmaceutical market research firm. In its monthly review of the local market, IMS Health said in its ... Read More »

FDA approves Wellstat’s Vistogard for chemotherapy overdose The US Food and Drug Administration (FDA) has approved Wellstat Therapeutics’ Vistogard (uridine triacetate) to treat overdose of fluorouracil or capecitabine, which are administered for several malignancies. Vistogard is claimed to be the first antidote for emergency treatment of 5-fluorouracil (5-FU) overdose treatment available to patients. It is also indicated for patients exhibiting ... Read More »

Bial’s Zebinix meets primary endpoint in phase 3 study for patients with newly diagnosed partial-onset seizures Bial has unveiled positive results for a pivotal phase 3 non-inferiority study comparing the efficacy and safety of eslicarbazepine acetate (ESL) to controlled release carbamazepine (CBZ-CR) as monotherapy in newly diagnosed adult patients with partial-onset seizures (POS). Bial director of research & development department ... Read More »

Can Pfizer finally orchestrate a winning megamerger after so many disappointments? Pfizer’s ($PFE) decision to buy Allergan ($AGN) wasn’t much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEO Ian Read‘s desired tax inversion. Nor is it surprising that Pfizer chose to rack up another megamerger, given its history of huge deals. ... Read More »

Heptares Therapeutics, Pfizer partner for GPCR-focused drug discovery Heptares Therapeutics and Pfizer have signed a drug discovery collaboration agreement, focused on G protein-coupled receptor (GPCR) targets across several therapeutic areas. Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer stabilized GPCRs ... Read More »

Mega Merger: Pfizer and Allergan to combine Pfizer and Allergan to merge in a $160 billion deal Pfizer and Allergan has announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a ... Read More »